Format

Send to

Choose Destination
CNS Oncol. 2017 Apr;6(2):95-99. doi: 10.2217/cns-2016-0034.

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors.

Roque A1,2, Odia Y1,2.

Author information

1
Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.
2
Department of Neurology, Columbia University Medical School, New York, NY, USA.

Abstract

We present a patient with BRAF-V600E mutant papillary craniopharyngioma successfully treated with combination BRAF (dabrafenib 150 mg twice daily) and MEK (trametinib 2 mg daily) inhibitors after her unresectable tumor proved refractory to radiation. Serial brain MRIs and PET revealed marked tumor reduction with gradual neurological improvement and permanent panhypopituitarism.

KEYWORDS:

BRAF V600E; craniopharyngioma; dabrafenib; trametinib

PMID:
28425764
PMCID:
PMC6020871
DOI:
10.2217/cns-2016-0034
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center